Abstract:The Fan1 endonuclease is required for repair of DNA interstrand cross-links (ICLs). Mutations in human Fan1 cause karyomegalic interstitial nephritis (KIN), but it is unclear whether defective ICL repair is responsible or whether Fan1 nuclease activity is relevant. We show that Fan1 nuclease-defective (Fan1 nd/nd ) mice develop a mild form of KIN. The karyomegalic nuclei from Fan1 nd/nd kidneys are polyploid, and fibroblasts from Fan1 nd/nd mice become polyploid upon ICL induction, suggesting that defective IC… Show more
“…Its efficient recruitment to mitomycin C (MMC)-induced DNA damage foci by ub-FANCD2 and the requirement of its UBZ domain in this process strongly implied a link between FAN1 and the FA pathway. However, this prediction was not substantiated by genetic data showing that FAN1 mutations segregate with KIN rather than with FA 10 – 12 . Moreover, FAN1-deficient cells are generally less sensitive to ICL-inducing agents than FA cells and, unlike FA cells, display no growth defects under normoxic conditions 7 .…”
Interstrand cross-link (ICL) hypersensitivity is a characteristic trait of Fanconi anemia (FA). Although FANCD2-associated nuclease 1 (FAN1) contributes to ICL repair, FAN1 mutations predispose to karyomegalic interstitial nephritis (KIN) and cancer rather than to FA. Thus, the biological role of FAN1 remains unclear. Because fork stalling in FAN1-deficient cells causes chromosomal instability, we reasoned that the key function of FAN1 might lie in the processing of halted replication forks. Here, we show that FAN1 contains a previously-uncharacterized PCNA interacting peptide (PIP) motif that, together with its ubiquitin-binding zinc finger (UBZ) domain, helps recruit FAN1 to ubiquitylated PCNA accumulated at stalled forks. This prevents replication fork collapse and controls their progression. Furthermore, we show that FAN1 preserves replication fork integrity by a mechanism that is distinct from BRCA2-dependent homologous recombination. Thus, targeting FAN1 activities and its interaction with ubiquitylated PCNA may offer therapeutic opportunities for treatment of BRCA-deficient tumors.
“…Its efficient recruitment to mitomycin C (MMC)-induced DNA damage foci by ub-FANCD2 and the requirement of its UBZ domain in this process strongly implied a link between FAN1 and the FA pathway. However, this prediction was not substantiated by genetic data showing that FAN1 mutations segregate with KIN rather than with FA 10 – 12 . Moreover, FAN1-deficient cells are generally less sensitive to ICL-inducing agents than FA cells and, unlike FA cells, display no growth defects under normoxic conditions 7 .…”
Interstrand cross-link (ICL) hypersensitivity is a characteristic trait of Fanconi anemia (FA). Although FANCD2-associated nuclease 1 (FAN1) contributes to ICL repair, FAN1 mutations predispose to karyomegalic interstitial nephritis (KIN) and cancer rather than to FA. Thus, the biological role of FAN1 remains unclear. Because fork stalling in FAN1-deficient cells causes chromosomal instability, we reasoned that the key function of FAN1 might lie in the processing of halted replication forks. Here, we show that FAN1 contains a previously-uncharacterized PCNA interacting peptide (PIP) motif that, together with its ubiquitin-binding zinc finger (UBZ) domain, helps recruit FAN1 to ubiquitylated PCNA accumulated at stalled forks. This prevents replication fork collapse and controls their progression. Furthermore, we show that FAN1 preserves replication fork integrity by a mechanism that is distinct from BRCA2-dependent homologous recombination. Thus, targeting FAN1 activities and its interaction with ubiquitylated PCNA may offer therapeutic opportunities for treatment of BRCA-deficient tumors.
“…It is possible that FAN1 may respond to a subset of ICLs that is somehow different in nature from the ICLs dealt with by the FA pathway. This might re ect a difference in the chemical nature of the ICLs or a difference in the genomic context of the ICLs recognized by the two pathways [37].…”
Karyomegalic interstitial nephritis (KIN) is a rare disease entity that was first described by Burry in 1974 and given this term by Mihatsch 1979 and al five years later. KIN is characterized by chronic tubulo-interstitial nephritis associated with enlarged tubular epithelial cell nuclei, which leads to progressive decline of renal function. The prevalence of this disease is less than 1% and its pathogenesis is unclear. KIN results from the mutation in the FAN 1 (FANCD2/FANCI-Associated Nuclease 1) gene, a gene involved in the DNA damage response pathway, particularly in the kidney. KIN seems to be rather multifactorial involving an environmental factor Ochratoxin A (OTA) but especially a genetic predisposition. In this article, we report 6 additional cases of KIN with histological evidence in 3 patients. Family clustering and differences in susceptibility to develop the nephropathy in spite of a high OTA contamination in all subjects show that there is a genetic susceptibility. So we completed our explorations by a genetic study. This study allowed us to identify novel mutations in the FAN1 gene in the affected members. To our best knowledge, this is the first Tunisian study involving familial cases of KIN with mutations on the FAN1 gene.
“…However, a number of studies suggested that the cross-link repair function of FAN1 is not within the FA pathway as: (i) homologs of FAN1 have been found in bacteria, archaea, and unicellular eukaryotes which lack FA proteins (19,(21)(22)(23), (ii) mutations in FAN1 do not cause FA, but instead a kidney disorder called karyomegalic interstitial nephritis (KIN) (24), (iii) N-terminal UBZ domain is dispensable for ICL repair, but is required for genomic maintenance, suggesting that the interaction of FAN1 with ID serves a function outside of ICL repair (25)(26)(27). Nevertheless, the sensitivity of FAN1-deficient cells to ICL-forming agents implicates FAN1 in ICL resolution independently of the FA pathway.…”
Section: Dna Synthesis (Tls) and The Second Strand Is Repaired By Hommentioning
The mechanism of ICL unhooking by bacterial FAN1 4 a "head to tail" dimer in the presence of DNA (34).The authors suggest that FAN1 dimer scans, latches, and unwinds DNA to pull the single-stranded DNA to the active site of a FAN1. Mutations of the residues at the dimeric interface abolished the nuclease activity of the HsFAN1, raising the possibility that the dimerization is important for its activity.Bacterial FAN1 homologs share a high similarity with HsFAN1 (Fig. 1A, 23,35). Second, PaFAN1 does not have a specific basic pocket that is critical for the proposed "3-nt exonuclease" mechanism (Fig. 1B, C, 33). Third, PaFAN1 lacks the basic motif in the SAP domain required for dimerization in one of the structures of the human nuclease (Fig. 1A, 34). These features raise the question if PaFAN1 can unhook ICLs, and if so, by which mechanism.To address these issues, we examined the ICL Based on these findings, we provide insights into how FAN1 might have evolved to have two basic regions to guide its nuclease activity and maintain genomic stability.
RESULTS
Substrate specificity of PaFAN1In previous study, we have used a DNA substrate with a four nucleotide 5' flap (23). (Fig. S1E-F).
PaFAN1 efficiently incises ICL lesionTo examine whether the bacterial FAN1homolog shares the ICL resolving activity of mammalian FAN1, we examined the in vitro ICL unhooking activity of PaFAN1 using various DNA ICL substrates (Fig. 1D). We first analyzed ifPaFAN1 can unhook the ICL near the ss/ds junction.We used DNA substrates containing a nitrogen-like ICL, which is free of duplex distortion (15,36,37), The mechanism of ICL unhooking by bacterial FAN1 7 how PaFAN1 can catalyze multiple cleavage events.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.